API small molecule and ADC manufacturer Axplora has inaugurated a novel payload manufacturing workshop at its Le Mans, France site.
The expansion, which is part of the France 2030 programme, will build on Axplora's commercial ADC manufacturing capacity significantly.
Specifically, the new GMP workshop will be able to produce up to 1.5kg of product per batch, with a dedicated Hastelloy filter dryer ensuring employee safety and API containment.
Through this extension, Axplora will be able to produce large quantities of cytotoxic payloads for its customers, while also offering them enhanced scalability.
The Le Mans site now features six ADC workshops dedicated to commercial payload and payload-linker production and bioconjugation, which streamlines project management initiatives for the company's clients.
It also houses four small and large-scale purification lines which use high-performance chromatography to produce quality cytotoxics.
Currently, the company supplies 40% of the world's commercially available and marketed ADCs — though the company hopes to raise this figure through its manufacturing investments.
“This expansion is a bold step forward in our mission to support clients at every stage of ADC development and manufacturing,” stated Arul Ramadurai, Chief Commercial Officer.
“By combining state-of-the-art payload manufacturing with our proven expertise in purification and bioconjugation, we’re enabling pharmaceutical innovators to accelerate drug development and deliver transformative treatments to patients faster.”
“The addition of this new payload manufacturing asset demonstrates our dedication to equipping clients with the cutting-edge tools and capabilities needed to develop the next generation of life-saving therapies," concluded Rachel de Luca, Site Director, Le Mans.